Compare Stocks: CALC, IXHL, NTRB, and ADXS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.60	$0.60	$0.00 ▼ $0.80	$35.79M	1.75	15,632 shs	N/A
CALC CalciMedica	$0.68	$0.81	$0.46 ▼ $7.20	$10.67M	0.91	300,554 shs	120,715 shs
IXHL Incannex Healthcare	$3.28	$3.36	$2.49 ▼ $27.69	$39.26M	6.98	91,612 shs	100,334 shs
NTRB Nutriband	$3.30	$3.09	$2.80 ▼ $8.63	$40.13M	1.98	6,782 shs	4,139 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+1,026.03%
CALC CalciMedica	0.00%	-1.80%	-8.22%	+8.89%	-76.80%
IXHL Incannex Healthcare	0.00%	+4.13%	+3.47%	-13.46%	-71.24%
NTRB Nutriband	0.00%	+6.11%	+6.11%	-4.60%	-49.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.60	$0.60	$0.00 ▼ $0.80	$35.79M	1.75	15,632 shs	N/A
CALC CalciMedica	$0.68	$0.81	$0.46 ▼ $7.20	$10.67M	0.91	300,554 shs	120,715 shs
IXHL Incannex Healthcare	$3.28	$3.36	$2.49 ▼ $27.69	$39.26M	6.98	91,612 shs	100,334 shs
NTRB Nutriband	$3.30	$3.09	$2.80 ▼ $8.63	$40.13M	1.98	6,782 shs	4,139 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+1,026.03%
CALC CalciMedica	0.00%	-1.80%	-8.22%	+8.89%	-76.80%
IXHL Incannex Healthcare	0.00%	+4.13%	+3.47%	-13.46%	-71.24%
NTRB Nutriband	0.00%	+6.11%	+6.11%	-4.60%	-49.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXS Ayala Pharmaceuticals	0.00	N/A	N/A	N/A
CALC CalciMedica	2.00	Hold	$10.00	1,381.26% Upside
IXHL Incannex Healthcare	2.00	Hold	$18.00	448.78% Upside
NTRB Nutriband	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest CALC, IXHL, NTRB, and ADXS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	CALC CalciMedica	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/29/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/17/2026	IXHL Incannex Healthcare	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/7/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/1/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/17/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/8/2026	IXHL Incannex Healthcare	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$18.00
6/3/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXS Ayala Pharmaceuticals	$3.24M	11.05	N/A	N/A	($2.06) per share	-0.29
CALC CalciMedica	N/A	N/A	N/A	N/A	($0.46) per share	N/A
IXHL Incannex Healthcare	$90K	436.24	N/A	N/A	$2.07 per share	1.58
NTRB Nutriband	$2.04M	19.67	N/A	N/A	$0.55 per share	6.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXS Ayala Pharmaceuticals	-$48.07M	-$5.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	-$29.56M	-$1.36	N/A	N/A	N/A	N/A	-863.40%	-155.24%	N/A
IXHL Incannex Healthcare	-$46.88M	-$1.55	N/A	N/A	N/A	N/A	-81.01%	-76.11%	9/2/2026 (Estimated)
NTRB Nutriband	-$8.23M	-$2.58	N/A	N/A	N/A	-448.25%	-112.64%	-97.86%	9/30/2026 (Estimated)

Latest CALC, IXHL, NTRB, and ADXS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2026	Q2 2026	CALC CalciMedica	-$0.2850	-$0.45	-$0.1650	-$0.45	N/A	N/A
6/11/2026	Q1 2027	NTRB Nutriband	N/A	-$0.10	N/A	-$0.10	N/A	$0.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A
CALC CalciMedica	1.67	5.58	5.58
IXHL Incannex Healthcare	N/A	41.56	41.56
NTRB Nutriband	N/A	5.26	5.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXS Ayala Pharmaceuticals	7.18%
CALC CalciMedica	N/A
IXHL Incannex Healthcare	0.43%
NTRB Nutriband	19.70%

Insider Ownership

Company	Insider Ownership
ADXS Ayala Pharmaceuticals	0.63%
CALC CalciMedica	28.25%
IXHL Incannex Healthcare	1.33%
NTRB Nutriband	52.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXS Ayala Pharmaceuticals	20	59.31 million	42.36 million	Not Optionable
CALC CalciMedica	30	15.80 million	11.34 million	No Data
IXHL Incannex Healthcare	3	11.97 million	11.81 million	Not Optionable
NTRB Nutriband	10	12.16 million	5.81 million	Not Optionable

CALC, IXHL, NTRB, and ADXS Headlines

Recent News About These Companies

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

August 13, 2026 | globenewswire.com

Nutriband shareholders approve proposals and expand board leadership

June 23, 2026 | theglobeandmail.com

Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference

May 15, 2026 | globenewswire.com

Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast

April 22, 2026 | globenewswire.com

Nutriband Advances Lead Abuse-Deterrent Fentanyl Patch Branding

April 7, 2026 | tipranks.com

Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

March 30, 2026 | globenewswire.com

Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica

March 18, 2026 | finance.yahoo.com

Nutriband Wins Costa Rica OK for Product

March 18, 2026 | baystreet.ca

Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica

February 17, 2026 | globenewswire.com

Nutriband Cancels Planned Sale of Pocono Pharmaceuticals

February 14, 2026 | theglobeandmail.com

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points

January 30, 2026 | globenewswire.com

The past five years for Nutriband (NASDAQ:NTRB) investors has not been profitable

January 29, 2026 | finance.yahoo.com

Nutriband says ‘committed’ to shareholder value as ‘number one focus’

January 1, 2026 | finance.yahoo.com

Nutriband Inc. CEO Shares 2025 Achievements and 2026 Outlook in Letter to Shareholders

December 31, 2025 | quiverquant.comQ

Nutriband CEO Publishes Letter to Shareholders

December 31, 2025 | globenewswire.com

Nutriband Divests Pocono Stake to Fund AVERSA Fentanyl

December 30, 2025 | tipranks.com

What’s driving Nutriband shares higher today?

December 29, 2025 | msn.com

Nutriband stock soars on sale of Pocono Pharmaceutical stake

December 29, 2025 | za.investing.com

Nutriband Inc. Sells 90% Stake in Pocono Pharmaceutical to Earthvision Bio for $5 Million

December 29, 2025 | quiverquant.comQ

Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio

December 29, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC, IXHL, NTRB, and ADXS Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

$0.60 0.00 (0.00%)

As of 08/14/2026

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

CalciMedica NASDAQ:CALC

$0.68 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.70 +0.03 (+3.84%)

As of 08/14/2026 07:33 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Incannex Healthcare NASDAQ:IXHL

$3.28 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.26 -0.02 (-0.76%)

As of 08/14/2026 07:34 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Nutriband NASDAQ:NTRB

$3.30 0.00 (0.00%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$3.25 -0.05 (-1.52%)

As of 08/14/2026 07:34 PM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CALC, IXHL, NTRB, and ADXS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CALC, IXHL, NTRB, and ADXS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CALC, IXHL, NTRB, and ADXS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC, IXHL, NTRB, and ADXS Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

CalciMedica NASDAQ:CALC

Incannex Healthcare NASDAQ:IXHL

Nutriband NASDAQ:NTRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CALC, IXHL, NTRB, and ADXS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CALC, IXHL, NTRB, and ADXS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CALC, IXHL, NTRB, and ADXS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC, IXHL, NTRB, and ADXS Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

CalciMedica NASDAQ:CALC

Incannex Healthcare NASDAQ:IXHL

Nutriband NASDAQ:NTRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools